Over the previous 5 years, medications called GLP-1s have actually transformed the treatment of metabolic conditions like weight problems, diabetes and fatty liver illness.

Offered under the brand Ozempic, Wegovy, Mounjaro and Zepbound, these drugs are extremely efficient at assisting individuals drop weight and handle their blood sugar level levels.

They do come with some dangers. Some individuals taking GLP-1s experience queasiness and other intestinal negative effects that can be challenging to handle.

And, by reducing cravings and decreasing food consumption, they have the possible to trigger dietary shortages and muscle loss, which can result in frailty and other issues long term.

“Body weight reacts to 2 levers: taking in less calories, or investing more energy,” stated University of California, Berkeley’s Professor Anders Näär, senior author of a brand-new research study.

“GLP-1s work nearly totally on the very first, so we pursued the 2nd.”

In the research study, Professor Näär and his associates concentrated on an orally bioavailable molecular substance called 5-tetradecyloxy-2-furoic acid (TOFA).

The substance was very first studied in the 1970s and 1980s as an inhibitor of fat-producing enzymes, however was never ever evaluated for its more comprehensive impacts on weight problems or assessed in human beings.

In the brand-new experiments in mice, TOFA produced remarkable outcomes: a typical 18% decrease in body weight, enhanced blood sugar level control, and significant enhancement in fatty liver illness– all without reducing cravings or triggering muscle loss.

Especially, the drug prevented an unsafe negative effects– increasing blood triglycerides– that has actually weakened other drugs in its class.

The scientists traced this to an unanticipated 2nd system: TOFA likewise triggers proteins called PPAR receptors, which control the body’s energy-burning procedures.

“TOFA appears to engage a collaborated metabolic action,” stated very first author Dr. Justin Lee, a scientist at the University of California, Berkeley.

“It is not just obstructing lipid synthesis. It is likewise triggering energy expense paths that might assist the body deal with excess lipid and glucose better.”

When integrated with popular weight-loss drugs semaglutide (Ozempic) and tirzepatide (Zepbound), TOFA produced even higher weight-loss than either drug alone.

Mice offered TOFA likewise kept weight off longer after treatment stopped, compared to those on semaglutide, which the researchers credit to its unique system of targeting energy usage instead of food consumption.

The authors warn that security and dosing in human beings still require to be developed before any scientific trials might start.

“In our mix experiments, TOFA worked additively or synergistically with the GLP-1 cravings reducing drugs, so we see it as complementary instead of as a replacement,” Professor Näär stated.

The findings appear in the journal Science Advances

_____

Justin Y. Lee et al2026. A multi-functional oral little particle targeting energy and lipid metabolic process to deal with weight problems and associated metabolic conditions. Science Advances 12 (34 ); doi: 10.1126/ sciadv.aed3119